Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levofloxacin.

S R Norrby1

  • 1Division of Infectious Diseases, Department of Infectious Diseases and Medical Microbiology, University of Lund, Lund University Hospital, SE-22185 Lund, Sweden. Ragnar.Norrby@infek.lU.se

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2004
Same author

S Ragnar Norrby--Director General of the Swedish Institute for Infectious Disease Control. Interview by Pam Das.

The Lancet. Infectious diseases·2002
Same author

Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis.

Scandinavian journal of infectious diseases·2002
Same author

Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.

Chemotherapy·2001
Same author

Urinary tract infections: disease panorama and challenges.

The Journal of infectious diseases·2001
Same author

Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.

The Journal of antimicrobial chemotherapy·2001

Levofloxacin, the active isomer of ofloxacin, offers significantly enhanced antibacterial activity and favorable pharmacokinetics. This fluoroquinolone demonstrates a strong safety profile, making it a valuable option for treating various infections.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Levofloxacin is the S-(-)-enantiomer of ofloxacin, a widely used fluoroquinolone antibiotic.
  • The development of levofloxacin aimed to improve upon the efficacy and safety profile of existing fluoroquinolones.

Purpose of the Study:

  • To evaluate the in vitro activity, pharmacokinetics, and clinical efficacy of levofloxacin.
  • To compare levofloxacin's properties with those of ofloxacin and other fluoroquinolones.

Main Methods:

  • In vitro susceptibility testing against various bacterial pathogens.
  • Pharmacokinetic studies assessing bioavailability, protein binding, tissue distribution, and elimination.
  • Clinical trials evaluating safety and efficacy in lower respiratory tract, skin and soft tissue, and urinary tract infections.

Related Experiment Videos

Main Results:

  • Levofloxacin exhibits 8-128 times greater in vitro activity than ofloxacin against key pathogens.
  • It demonstrates excellent oral bioavailability, high tissue penetration, and minimal hepatic metabolism.
  • Clinical studies confirm efficacy in common infections with a favorable safety profile, including low risks of phototoxicity, CNS, and cardiac events.

Conclusions:

  • Levofloxacin represents a significant advancement in fluoroquinolone therapy due to its enhanced potency and favorable pharmacokinetic and safety profiles.
  • It is a valuable therapeutic option for bacterial infections, particularly where susceptibility to older agents is borderline.